XNAS
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | Q1 2026 | — | -6.71 | — | $21,457 | — | +1.62% | -71.58% | — |
| 2025-11-13 | Q3 2025 | — | -6.25 | — | $303,651 | — | — | — | — |
| 2024-12-10 | Q3 2024 |
| — |
| -2.93 |
| — |
| $406,859 |
| — |
| -4.70% |
| -26.68% |
| -20.44% |
| 2024-08-29 | Q2 2024 | 0.40 | -25.60 | -6500.00% | $704,848 | ❌ Miss | +1.34% | -5.15% | -2.99% |
| 2024-05-20 | Q1 2024 | — | -20.00 | — | $700,433 | — | -15.98% | +3.15% | -2.45% |
| 2024-04-11 | Q4 2023 | — | -52.00 | — | $58,465 | — | -10.19% | -15.18% | -27.35% |
| 2023-11-17 | Q3 2023 | -5.60 | -11.20 | -100.00% | $0 | ❌ Miss | — | — | — |
| 2023-10-20 | Q2 2023 | -6.00 | -17.20 | -186.67% | $0 | ❌ Miss | — | — | — |
Showing last 8 quarters.